Despite the availability of highly effective, curative oral antivirals for over a decade, Hepatitis C (HCV) remains a persistent public health crisis. In 2023 alone, an estimated 69,000 Americans acquired the virus—a figure roughly double the infection rates observed in the mid-2010s. While medical science has moved from the era of ineffective, side-effect-heavy interferon injections to the age of precision direct-acting antivirals (DAAs), the path to eradication is increasingly blocked by administrative hurdles and the challenges of reaching vulnerable populations.
Central to this landscape is AbbVie’s Maviret (glecaprevir/pibrentasvir). With its recent regulatory expansions, the drug is positioned as a cornerstone in the fight against both chronic and acute HCV. However, as the medical community looks beyond the near-perfect efficacy rates seen in clinical trials, the central question remains: Is this medical breakthrough reaching the patients most in need?
The Evolution of HCV Treatment: A Chronology
The journey toward modern HCV treatment has been marked by significant leaps in virologic success.
- 1991: The U.S. FDA approves the first treatment for HCV, an alpha-interferon injection. It was a breakthrough at the time, yet it offered only a 10% viral eradication rate, leaving the vast majority of patients with a chronic, life-altering condition.
- 2017: AbbVie receives approval from both the European Union and the U.S. FDA for Maviret to treat chronic HCV across all major genotypes (GT 1-6) with a shortened treatment window of as little as eight weeks.
- June 2025: The FDA grants a landmark label expansion for Maviret, making it the first antiviral cleared specifically for acute HCV infection. This move signaled a shift in clinical strategy, moving away from "wait and see" approaches.
- June 2026: The European Commission follows suit, approving the expanded indication for Maviret to treat acute HCV in the EU. This regulatory alignment across major markets acknowledges that waiting for a disease to become chronic is a public health failure.
Clinical Efficacy vs. Real-World Effectiveness
The clinical evidence supporting Maviret is, by almost any metric, profound. In Phase 3 trials evaluating the drug for acute infection, the results were stellar: a sustained virologic response (SVR) rate of 96.2% at 12 weeks in the intention-to-treat population. When excluding non-virologic failures, that success rate climbed to 100%. Perhaps most impressively, there were no reported on-treatment virologic failures or post-treatment relapses.
However, the "real world" operates with far more friction than a controlled trial environment. The clinical success of Maviret is undeniable, but its effectiveness in the field depends on the speed of diagnosis and the removal of bureaucratic barriers.
Dr. Ivan Gentile, an infectious disease specialist at the University of Naples Federico II and a co-author of the trial, emphasizes that the previous medical paradigm was actively counterproductive. "Before the acute indication, patients could be required to wait for confirmation of chronicity, even though current clinical guidelines support treatment as soon as acute infection is diagnosed," Gentile noted. "That delay can add unnecessary visits, create administrative barriers, and, most importantly, increase the risk that patients disengage from care."
The Challenge of Recurrent Infections
One of the most revealing aspects of the recent Phase 3 trials was the participation of individuals with a history of HCV. Approximately 18% of trial participants were being treated for at least their second HCV infection, with nearly 40% of those individuals having experienced two or more prior infections. In two extreme cases, participants were being treated for their sixth infection.
Critically, the data suggests that prior exposure does not build "resistance" in a way that limits future treatment. "The study found that a history of prior HCV infection did not appear to affect the SVR," Dr. Gentile explained. "These findings suggest that neither prior infection nor previous exposure to the same regimen compromised the virologic response to treatment of the current episode."
This is a vital finding for public health. It suggests that "reinfection" should not be viewed as a clinical failure or a reason to withhold treatment. Instead, it serves as a diagnostic signal that the patient is part of a high-risk demographic—such as those who inject drugs or those with ongoing sexual exposure risks—who require a more integrated approach to care.
Bridging the Gap: Integrating Prevention and Treatment
While the clinical data is robust, experts warn against the "medicalization" of a disease that is fundamentally driven by social and behavioral factors. The systematic review of over 6,000 person-years of data found that reinfection rates among people who inject drugs are approximately 5.9 per 100 person-years, significantly higher than the general population rate of 1.27 per 100 person-years.
"Antiviral treatment does not modify the underlying exposure," Dr. Gentile noted. For treatment to be truly effective, it must be embedded within a broader "harm reduction" framework. This includes:
- Accessibility: Providing sterile injecting equipment to reduce transmission vectors.
- Support: Offering integrated treatment for substance-use disorders.
- Education: Implementing robust sexual-health interventions.
- Infrastructure: Facilitating regular HCV RNA testing and, crucially, rapid retreatment pathways for those who become reinfected.
From an elimination perspective, the goal is not merely to treat the individual but to interrupt the chain of transmission within the community. In this context, those with repeated infections are not "lost causes," but rather the individuals for whom rapid treatment provides the greatest public health value.
Limitations and Future Directions
Despite the optimism surrounding the label expansion of Maviret, there is a clear acknowledgment that the clinical trial population did not perfectly mirror the most marginalized communities. Only 14.3% of the Phase 3 trial participants were people who currently or recently injected drugs. Furthermore, while nearly 50% of the participants were HIV-positive, all were already receiving antiretroviral therapy and were, therefore, consistently connected to the healthcare system.
This "selection bias" toward patients already engaged in care likely contributed to the trial’s low dropout rate. It remains an open question how well these results will translate to patients who have unstable or non-existent connections to the formal healthcare system.
"This study provides strong evidence of antiviral efficacy, but it does not fully answer the question of effectiveness in populations that are least engaged in care," Gentile admitted. The next frontier in HCV elimination is not necessarily developing a "better" drug, but developing a better delivery system. Future studies must pivot to measure real-world performance indicators: the proportion of diagnosed patients who actually begin treatment, the time elapsed from diagnosis to the first dose, and the ability to maintain engagement despite the social challenges patients may face.
The Path Forward: Eliminating Barriers
The approval of the acute indication for Maviret is a victory for clinical efficiency. By removing the requirement for clinicians to wait for confirmation of chronicity, the FDA and the European Commission have effectively lowered the administrative wall that previously stood between a patient and their cure.
As John Ward, director of the Coalition for Global Hepatitis Elimination, stated, "If treated early with safe and effective therapies, providers can cure virtually all patients with hepatitis C before it escalates to chronic disease."
The task ahead is to ensure that this medical mandate is met with equivalent political and social will. If the goal is to truly eliminate Hepatitis C, the medical community must stop viewing reinfection as a clinical deterrent and start viewing it as a prompt for improved, holistic care. Maviret has provided the weapon; the challenge now is to ensure it reaches the front lines of the epidemic. As the industry looks to 2027 and beyond, the success of HCV elimination will be measured not just in SVR percentages, but in the ability of health systems to reach those who have been left behind by the traditional, office-based model of medicine.
About the Author
